U Magazine
U Magazine
UCLA Health
 
David Geffen School of Medicine
 
ISSUE VIEWING
IN THIS ISSUE
MOST POPULAR
The Cutting Edge

UCLA Scientists Advance Cancer-screening Technology to Personalize Treatment

  UCLA Scientists Advance Cancer-screening Technology to Personlize Treatment  
 

Parallel microfluidic vortex chambers accumulate
larger circulating tumor cells from flowing blood.
Image: Courtesy of Dr. Dino Di Carlo

Despite a growing interest in developing noninvasive methods to identify rare cancer cells or cancer-cell DNA in blood, current techniques remain complicated and often prohibitively expensive. Now, UCLA researchers have pioneered a more effective approach to these “liquid biopsies” that has the potential to offer a streamlined and low-cost solution for people with the disease.

The technology works by creating millimeter-scale whirlpools to draw in and concentrate circulating tumor cells, known as CTCs, based on their size. CTCs often appear as large abnormal cells in the circulation of cancer patients and can be used by scientists as cellular markers of the disease. Analysis of these cells promises to provide critical information about which treatments are best suited and most effective for a patient and whether or not those receiving a therapy may relapse.

“CTCs are extremely rare, so isolating them is a problem similar to finding a needle in a haystack,” says Dino Di Carlo, PhD, director of UCLA’s Jonsson Comprehensive Cancer Center Nanotechnology Program and professor of bioengineering at UCLA’s Henry Samueli School of Engineering and Applied Science. “Our filterless system avoids issues of previous technologies that clog and break cells apart, and we found this approach was more effective than technologies currently available at isolating cells from breast- and lung-cancer patients.”

In a two-year study, Dr. Di Carlo’s team isolated cells and detected specific proteins on these cells from 50 patients. In a subset of these patients, they compared the number of CTCs discovered by the U.S. Food and Drug Administration-approved gold-standard instrument. What they found was a significantly higher number of cells per patient, with more than 80 percent of patients having CTC levels above age-matched healthy individuals, compared to only 20 percent with the currently approved instrument.

In a previous study published in 2014, the researchers discovered that the micro-whirlpools, or vortices, entrapped cancer cells with epithelial characteristics in a small number of patients (epithelial cells help to protect or enclose organs within the body). The new findings showed that nearly half of the CTCs isolated with this new Vortex HT system developed by UCLA researchers didn’t have epithelial-like markers and that the number of CTCs isolated was almost doubled compared to the previous iteration of the technology.

Dr. Di Carlo said he hopes the new system will enable clinicians to better understand how to administer and monitor treatments. In the long term, he hopes an approach could potentially be used to detect cancer earlier with a simple blood test.

“Classification of Large Circulating Tumor Cells Isolated with Ultra-high Throughput Microfluidic Vortex Technology,” Oncotarget, February 6, 2016

 





Add a comment


Please note that we are unable to respond to medical questions. For information about health care, or if you need help in choosing a UCLA physician, please contact UCLA Physician Referral Service (PRS) at 1-800-UCLA-MD1 (1-800-825-2631) and ask to speak with a referral nurse. Thank you.